Shots:
- Boomray Pharmaceuticals has entered into an exclusive global license agreement with Novartis for an undisclosed preclinical radioligand therapy (RLT) asset
- As per the deal, BoomRay will receive ~$900M, incl. an upfront payment as well as development, regulatory, & sales milestone payments, with royalties on future global net sales
- Agreement combines BoomRay’s discovery & development capabilities with Novartis’ global RLT expertise to advance therapies aimed at delivering meaningful benefits to pts worldwide
Ref: PRnewswire | Image: BoomRay & Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
